HOUSTON

,

May 11, 2021

/PRNewswire/ —


CNS Pharmaceuticals, Inc.


(NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that


John Climaco


, Chief Executive Officer of CNS Pharmaceuticals, will present at the

Q2 Virtual Investor Summit

on

Tuesday, May 18


^th

at

12:30 PM ET

.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the

conference website

.

A live

video webcast

will be accessible on the

Events

page in the

Investors

section of the Company’s website (

www.cnspharma.com

) and will be archived for 90 days following the event.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of

Feb. 20, 2020

. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. During 2021, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial (with extensive PK) in adults and a first-ever Phase 1 trial in pediatric GBM patients in

Poland

. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.

For more information, please visit

www.CNSPharma.com

.

View original content to download multimedia:

http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-q2-virtual-investor-summit-301288082.html

SOURCE CNS Pharmaceuticals, Inc.